ArticleBritish journal of cancer2017

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.

Li Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.